Publication:
An Overview of siRNA Delivery Strategies for Urological Cancers

Simple item page
dc.contributor.authorNadia Haliben_US
dc.contributor.authorNicola Pavanen_US
dc.contributor.authorCarlo Trombettaen_US
dc.contributor.authorBarbara Dapasen_US
dc.contributor.authorRossella Farraen_US
dc.contributor.authorBruna Scaggianteen_US
dc.contributor.authorMario Grassien_US
dc.contributor.authorGabriele Grassien_US
dc.date.accessioned2024-05-28T05:58:04Z
dc.date.available2024-05-28T05:58:04Z
dc.date.issued2022
dc.date.submitted2022-11-15
dc.descriptionPharmaceutics 2022, 14(4), 718en_US
dc.description.abstractThe treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.en_US
dc.identifier.citationHalib N, Pavan N, Trombetta C, Dapas B, Farra R, Scaggiante B, Grassi M, Grassi G. An Overview of siRNA Delivery Strategies for Urological Cancers. Pharmaceutics. 2022; 14(4):718. https://doi.org/10.3390/pharmaceutics14040718en_US
dc.identifier.doi10.3390/ pharmaceutics14040718
dc.identifier.doihttps://www.mdpi.com/1999-4923/14/4/718
dc.identifier.epage775
dc.identifier.issn1999-4923
dc.identifier.issue718
dc.identifier.other1667-25
dc.identifier.spage718
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/6881
dc.identifier.volume14
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofPharmaceuticsen_US
dc.subjectbladder cancer; prostate cancer; renal cancer; siRNA; deliveryen_US
dc.titleAn Overview of siRNA Delivery Strategies for Urological Cancersen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
An Overview of siRNA Delivery Strategies for Urological Cancers.pdf
Size:
2.12 MB
Format:
Adobe Portable Document Format
Download

Collections

Other Publications